Grufity logoGrufity logo

Reata Pharmaceuticals Inc Stock Research

RETA

88.53USD+2.84(+3.31%)Market Closed

Market Summary

USD88.53+2.84
Market Closed
3.31%

RETA Alerts

RETA Stock Price

RETA RSI Chart

RETA Valuation

Market Cap

3.2B

Price/Earnings (Trailing)

-10.37

Price/Sales (Trailing)

1.5K

EV/EBITDA

-10.27

Price/Free Cashflow

-15.59

RETA Price/Sales (Trailing)

RETA Profitability

EBT Margin

-14076.08%

Return on Equity

474.77%

Return on Assets

-60.62%

Free Cashflow Yield

-6.42%

RETA Fundamentals

RETA Revenue

Revenue (TTM)

2.2M

Revenue Y/Y

-100%

Revenue Q/Q

-100%

RETA Earnings

Earnings (TTM)

-311.9M

Earnings Y/Y

-0.14%

Earnings Q/Q

-8.23%

Price Action

52 Week Range

18.4795.00
(Low)(High)

Last 7 days

-0.9%

Last 30 days

98.9%

Last 90 days

161.1%

Trailing 12 Months

143.7%

RETA Financial Health

Current Ratio

6.75

RETA Investor Care

Shares Dilution (1Y)

0.41%

Diluted EPS (TTM)

-8.54

Peers (Alternatives to Reata Pharmaceuticals)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
402.9B
94.9B
-1.71% -11.01%
22.45
4.24
1.25% -14.07%
301.4B
28.5B
4.03% 16.86%
48.26
10.56
0.79% 11.88%
272.8B
59.3B
-2.02% 35.43%
17.88
4.63
21.72% 11.27%
225.5B
100.3B
-3.66% -21.92%
7.19
2.25
23.43% 42.74%
144.7B
46.2B
-3.01% -5.06%
22.87
3.14
-0.49% -9.54%
MID-CAP
4.6B
4.5B
-5.71% -9.25%
-32.73
1.03
7.56% -104.06%
3.2B
2.2M
98.90% 143.68%
-10.37
1.5K
-80.71% -4.88%
SMALL-CAP
1.9B
667.2M
-4.21% 13.64%
31.93
2.91
15.09% 13.64%
1.6B
602.5M
-7.75% -62.41%
-2.78
2.67
18.18% -18.59%
913.9M
478.9M
-19.31% -78.37%
-0.29
1.91
-31.50% -634.70%
787.4M
285.2M
-5.32% -41.91%
3.57
2.76
-27.21% -40.28%
745.9M
114.5M
-6.67% -53.88%
-4.42
6.52
27.90% 57.40%
542.8M
29.8M
-32.56% -54.58%
-6.25
18.25
340.05% 4.35%
396.8M
51.5M
-13.18% 0.78%
-5.59
7.71
18.32% -984.05%
94.1M
2.3B
-43.99% -88.43%
-0.03
0.04
-22.53% -376.66%

Financials for Reata Pharmaceuticals

Income Statement (Last 12 Months)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue-29.6%2,216,0003,149,00010,000,00011,459,00011,490,000
Operating Expenses2.6%280,250,000273,228,000267,687,000265,291,000256,198,000
  S&GA Expenses1.4%109,277,000107,816,000106,282,000103,137,00099,002,000
  R&D Expenses3.4%169,843,000164,236,000160,181,000160,916,000155,993,000
EBITDA-2.5%-310,796,000-303,155,000-298,089,000-290,070,000-
EBITDA Margin-362.6%-140-30.32-26.01-25.25-
Earnings Before Taxes-0.1%-311,926,000-311,535,000-304,379,000-304,176,000-297,836,000
EBT Margin-42.3%-140-98.93-30.44-26.54-25.92
Interest ExpensesNaN%0.000.00---
Net Income0.0%-311,901,000-311,784,000-304,628,000-303,773,000-297,386,000
Net Income Margin-42.2%-140-99.01-30.46-26.51-25.88
Free Cahsflow25.8%-207,537,000-279,869,000-275,826,000-250,299,000-237,030,000
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets-11.8%514584632680735
  Current Assets-10.6%398445491537596
    Cash Equivalents32.6%42.0032.00147532590
  Net PPE-0.7%11.0011.0011.0011.0012.00
  Current Liabilities16.3%59.0051.0046.0044.0054.00
Shareholder's Equity-1554.7%-65.695.0069.00128186
  Retained Earnings-5.8%-1,567-1,482-1,403-1,329-1,255
  Additional Paid-In Capital1.0%1,5021,4871,4721,4571,442
Accumulated Depreciation-15.00----
Shares Outstanding0.2%37.0036.0036.0036.00-
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations26.2%-204-276-272-248-235
  Share Based Compensation-0.4%59.0059.0058.0058.0057.00
Cashflow From Investing15.0%-345-405-337-1.42-1.33
Cashflow From Financing10.7%1.001.001.005.009.00

Risks for RETA

What is the probability of a big loss on RETA?

100%


Probability that Reata Pharmaceuticals stock will be more than 20% underwater in next one year

89.6%


Probability that Reata Pharmaceuticals stock will be more than 30% underwater in next one year.

80.4%


Probability that Reata Pharmaceuticals stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does RETA drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Reata Pharmaceuticals was unfortunately bought at previous high price.

Drawdowns

Returns for RETA

Cumulative Returns on RETA

34.7%


5-Year Cumulative Returns

-16.1%


3-Year Cumulative Returns

What are the long-term rolling returns for RETA?

FIve years rolling returns for Reata Pharmaceuticals.

Annualized Returns

Which funds bought or sold RETA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-23
MetLife Investment Management, LLC
reduced
-3.98
176,946
568,748
-%
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
sold off
-100
-294,000
-
-%
2023-03-06
Rockefeller Capital Management L.P.
added
17.2
107,000
245,000
-%
2023-03-02
OLIVER LAGORE VANVALIN INVESTMENT GROUP
new
-
4,065
4,065
-%
2023-02-28
Voya Investment Management LLC
unchanged
-
250,285
739,285
-%
2023-02-21
MACQUARIE GROUP LTD
sold off
-100
-70,000
-
-%
2023-02-16
HARBOUR INVESTMENTS, INC.
unchanged
-
342
342
-%
2023-02-15
ALLIANCEBERNSTEIN L.P.
added
224
3,428,750
4,305,750
-%
2023-02-15
Financial Gravity Asset Management, Inc.
reduced
-24.00
15.00
19.00
-%
2023-02-15
JANE STREET GROUP, LLC
new
-
1,961,230
1,961,230
-%

1–10 of 43

Latest Funds Activity

Are funds buying RETA calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own RETA
No. of Funds

Reata Pharmaceuticals News

Benzinga

Where Reata Pharmaceuticals Stands With Analysts - Reata ....

Benzinga,
17 hours ago

Investing.com UK

The Motley Fool

Business Wire

The Motley Fool

Genetic Engineering & Biotechnology News

StockWatch: Pfizer Scales Patent Cliff by Pursuing Seagen Deal.

Genetic Engineering & Biotechnology News,
26 days ago

InvestorPlace

Schedule 13G FIlings of Reata Pharmaceuticals

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 07, 2023
perceptive advisors llc
6.5%
2,083,799
SC 13G
Feb 14, 2023
first light asset management, llc
6.79%
2,155,552
SC 13G/A
Feb 14, 2023
point72 asset management, l.p.
0%
0
SC 13G/A
Feb 09, 2023
vanguard group inc
8.53%
2,705,656
SC 13G/A
Feb 03, 2023
blackrock inc.
7.9%
2,501,693
SC 13G/A
Sep 22, 2022
point72 asset management, l.p.
5.2%
1,650,400
SC 13G
Sep 09, 2022
wellington management group llp
4.78%
1,508,638
SC 13G/A
Apr 11, 2022
ecor1 capital, llc
6.3%
1,975,611
SC 13G
Mar 10, 2022
invesco ltd.
1.2%
372,165
SC 13G/A
Feb 10, 2022
invesco ltd.
7.2%
2,280,409
SC 13G/A

RETA Fair Value

Reata Pharmaceuticals fair value in different scenarios

The table shows the Fair Value estimates for Reata Pharmaceuticals for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

-

-

-

-

-

-

-

-

-

-
Current Inflation

0.02

-99.98%

0.02

-99.98%

0.03

-99.97%

0.04

-99.95%

0.06

-99.93%
Very High Inflation

-

-

-

-

-

-

-

-

-

-

Historical Reata Pharmaceuticals Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Reata Pharmaceuticals

View All Filings
Date Filed Form Type Document
Mar 15, 2023
4
Insider Trading
Mar 13, 2023
4
Insider Trading
Mar 09, 2023
4
Insider Trading
Mar 08, 2023
4
Insider Trading
Mar 08, 2023
4
Insider Trading
Mar 08, 2023
4
Insider Trading
Mar 08, 2023
4
Insider Trading
Mar 08, 2023
4
Insider Trading
Mar 08, 2023
4
Insider Trading
Mar 07, 2023
4
Insider Trading

Latest Insider Trading transactions for RETA

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-13
Bir Dawn Carter
sold
-808,436
86.77
-9,317
chief commercial officer
2023-03-10
Ruff Shamim
sold
-480,610
83.73
-5,740
-
2023-03-10
Ruff Shamim
acquired
198,042
34.5021
5,740
-
2023-03-07
WORTLEY MICHAEL D
sold
-34,966
84.46
-414
chief legal officer
2023-03-07
Bir Dawn Carter
acquired
-
-
41,630
chief commercial officer
2023-03-07
Loewen Andrea
sold
-1,588,140
83.4281
-19,036
svp, global regulatory affairs
2023-03-07
Khan Samina
sold
-330,585
83.46
-3,961
svp, chief medical officer
2023-03-07
Loewen Andrea
acquired
409,800
27.32
15,000
svp, global regulatory affairs
2023-03-07
Anand Bhaskar
sold
-13,955
84.58
-165
svp, chief accounting officer
2023-03-07
Soni Manmeet Singh
sold
-52,680
84.695
-622
coo, cfo and president

1–10 of 50

J. Warren Huff
350
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.

RETA Income Statement

2022-12-31
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Collaboration revenue   
Collaboration revenue$ 2,216$ 11,490$ 9,019
Expenses   
Research and development169,843155,993159,080
General and administrative109,27799,00275,128
Depreciation1,1301,2031,136
Total expenses280,250256,198235,344
Other income (expense), net(33,892)(53,128)(43,914)
Loss before taxes on income(311,926)(297,836)(270,239)
Benefit from taxes on income2545022,487
Net loss$ (311,901)$ (297,386)$ (247,752)
Net loss per share — basic$ (8.54)$ (8.19)$ (7.35)
Net loss per share — diluted$ (8.54)$ (8.19)$ (7.35)
Weighted-average number of common shares used in net loss per share — basic36,517,92836,321,35133,709,480
Weighted-average number of common shares used in net loss per share — diluted36,517,92836,321,35133,709,480
License and milestone   
Collaboration revenue   
Collaboration revenue$ 1,648$ 8,040$ 4,701
Other revenue   
Collaboration revenue   
Collaboration revenue$ 568$ 3,450$ 4,318

RETA Balance Sheet

2022-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Assets  
Cash and cash equivalents$ 42,312$ 590,258
Marketable debt securities345,2020
Prepaid expenses and other current assets10,2566,217
Total current assets397,770596,475
Property and equipment, net11,17911,604
Operating lease right-of-use assets105,258126,777
Other assets284160
Total assets514,491735,016
Liabilities and stockholders’ equity  
Accounts payable18,70613,505
Accrued direct research liabilities13,83614,249
Other current liabilities24,26721,450
Operating lease liabilities, current2,1513,142
Deferred revenue01,648
Total current liabilities58,96053,994
Operating lease liabilities, noncurrent117,313132,891
Liability related to sale of future royalties, net403,913362,142
Total noncurrent liabilities521,226495,033
Commitments and contingencies
Stockholders’ equity:  
Additional paid-in capital1,501,8001,441,584
Accumulated deficit(1,567,532)(1,255,631)
Total stockholders’ equity(65,695)185,989
Total liabilities and stockholders’ equity514,491735,016
Common Stock A  
Stockholders’ equity:  
Common stock value3231
Common Stock B  
Stockholders’ equity:  
Common stock value$ 5$ 5